All Releases
 |
BioCryst Announces Pricing of Public Offering of Common Stock
Nov 19, 2009
|
9.4 KB |
| |
BIRMINGHAM, Ala., Nov 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an eff...
|
|
BioCryst Announces Proposed Public Offering of Common Stock
Nov 17, 2009
|
9.4 KB |
| |
BIRMINGHAM, Ala., Nov 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst a...
|
|
BioCryst Receives First Peramivir Order From U.S. Government
Nov 5, 2009
|
11.2 KB |
| |
BIRMINGHAM, Ala., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health...
|
|
BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan
Nov 4, 2009
|
12.7 KB |
| |
BIRMINGHAM, Ala., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this...
|
|
BioCryst to Present at Oppenheimer Healthcare Conference
Oct 29, 2009
|
8.3 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co., Inc. 20th Annua...
|
|
BioCryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Oct 29, 2009
|
19.5 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
"BioCryst ...
|
|
Emergency Use Authorization Granted For BioCryst's Peramivir
Oct 23, 2009
|
11.5 KB |
| |
BIRMINGHAM, Ala., Oct 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigatio...
|
|
BioCryst Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
Oct 22, 2009
|
8.7 KB |
| |
BIRMINGHAM, Ala., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its third quarter 2009 financial results will be released on Thursday, October 29, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to p...
|
|
BioCryst to Present at JMP Securities Healthcare Conference
Oct 2, 2009
|
8.3 KB |
| |
BIRMINGHAM, Ala., Oct 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the JMP Securities Healthcare Focus Con...
|
|
BioCryst Clarifies Government Declaration Regarding Peramivir
Oct 2, 2009
|
11.0 KB |
| |
BIRMINGHAM, Ala., Oct 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Anti...
|
|
BioCryst Provides Update Regarding Peramivir for Influenza
Sep 30, 2009
|
13.4 KB |
| |
BIRMINGHAM, Ala., Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peram...
|
|
BioCryst Announces Initiation of Phase 2 Study of BCX4208 for the Treatment of Gout
Sep 28, 2009
|
11.8 KB |
| |
BIRMINGHAM, Ala., Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on ...
|
|
BioCryst Receives Peramivir Request for Proposal From the U.S. Government
Sep 21, 2009
|
10.3 KB |
| |
BIRMINGHAM, Ala., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patien...
|
|
BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Sep 21, 2009
|
12.7 KB |
| |
BIRMINGHAM, Ala., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (...
|
|
BioCryst to Present at UBS Global Life Sciences Conference
Sep 17, 2009
|
8.1 KB |
| |
BIRMINGHAM, Ala., Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, plans to provide a corporate summary at the UBS Global Life Sciences Conference in New York on Monday, September 21, 2009 at 3:00 p...
|
|
BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
Sep 15, 2009
|
12.9 KB |
| |
BIRMINGHAM, Ala., Sept 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and di...
|
|
BioCryst Executives to Present at Two Investor Conferences
Sep 8, 2009
|
8.4 KB |
| |
BIRMINGHAM, Ala., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that executives plan to provide corporate summaries at two upcoming investor conferences.
Dr. William P. Sheridan, Chief Medical Officer of BioCryst is scheduled to present a corporate summary at the Rodma...
|
|
BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
Jul 30, 2009
|
17.1 KB |
| |
BIRMINGHAM, Ala., July 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and six months ended June 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir in the U.S.
"Our...
|
|
BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Jul 28, 2009
|
8.4 KB |
| |
BIRMINGHAM, Ala., July 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provi...
|
|
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Jul 17, 2009
|
12.3 KB |
| |
BIRMINGHAM, Ala., July 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co., Ltd. of Osaka, Japan and conducted ...
|
|
|
